FNYS
JUNO

First New York Securities’s Juno Therapeutics, Inc. JUNO Stock Holding History

First New York Securities’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-740
Closed -$39.5K – 535
2015
Q2 		$39.5K Buy
+740
New +$39.3K 0.02% 215

Other funds holding JUNO

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GAMA
Graticule Asia Macro Advisors New York $649M AUM

First New York Securities's JUNO Position: Q3 2015 in Review

First New York Securities sold out of Juno Therapeutics, Inc. (JUNO) in Q3 2015, closing a stake of 740 shares — an estimated $39.5K sold.

First New York Securities first reported a position in JUNO in Q2 2015 and held it in 1 quarter. The position peaked at $39.5K in Q2 2015. 132 funds tracked by Wall St. Rank hold JUNO as of Q3 2015.

  • First New York Securities reported no remaining Juno Therapeutics, Inc. position as of Q3 2015 after selling out during the quarter.
  • First New York Securities sold 740 Juno Therapeutics, Inc. shares in Q3 2015, an estimated $39.5K.
  • First New York Securities first reported a position in Juno Therapeutics, Inc. in Q2 2015 and held it in 1 quarter.
  • First New York Securities's Juno Therapeutics, Inc. position peaked at $39.5K in Q2 2015.
  • 132 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q3 2015.

Based on First New York Securities's 13F filing for Q3 2015, filed 27 Oct 2015.